Health Care & Life Sciences » Pharmaceuticals | Peak Pharmaceuticals Inc.

Peak Pharmaceuticals Inc. | Income Statement

Fiscal year is October-September. All values USD Thousands.
2013
2014
2015
2016
2017
Cost of Goods Sold (COGS) incl. D&A
-
4.90
11.90
0.70
-
Gross Income
-
4.90
11.90
0.70
-
SG&A Expense
12.30
3,082.00
2,327.00
1,106.50
45.00
EBIT
12.30
3,086.80
2,338.90
1,105.80
45.00
Unusual Expense
-
24.70
-
18.20
5.00
Interest Expense
-
696.60
2.20
-
1.20
Pretax Income
12.30
3,758.80
2,341.10
1,087.50
51.20
Consolidated Net Income
12.30
3,758.80
2,341.10
1,087.50
51.20
Net Income
12.30
3,758.80
2,341.10
1,087.50
51.20
Net Income After Extraordinaries
12.30
3,758.80
2,374.10
1,012.80
51.20
Net Income Available to Common
12.30
3,758.80
2,308.00
1,081.30
51.20
EPS (Basic)
-
0.05
0.03
0.01
0.00
Basic Shares Outstanding
330,750.00
75,229.20
78,320.10
78,363.60
78,363.60
EPS (Diluted)
0.00
0.05
0.03
0.01
0.00
Diluted Shares Outstanding
330,750.00
75,229.20
78,320.10
80,919.60
78,363.60
EBITDA
12.30
3,082.00
2,327.00
1,106.50
45.00

About Peak Pharmaceuticals

View Profile
Address
700 North Colorando Boulevard
Denver Colorado 80206
United States
Employees -
Website -
Updated 07/08/2019
Peak Pharmaceuticals, Inc. manufactures and markets pharmaceutical level products containing phytocannabinoids, an abundant and pharmaceutically active component of industrial hemp for the prevention and alleviation of various conditions and diseases. The company was founded on December 18, 2007 and is headquartered in Denver, CO. .

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.